文献速递淋巴瘤

III/IV期经典霍奇金淋巴瘤患者的治疗偏好:CONNECT横断面调查结果

Patient preferences in the treatment of stage III/IV classic Hodgkin lymphoma: Results from the CONNECT cross-sectional survey.
PubMed 文献 · Br J Haematol · 2024-02-07

CONNECT在线横断面调查于2020年12月30日至2021年3月1日纳入美国182例过去10年内确诊的III/IV期经典霍奇金淋巴瘤成人患者,评估其一线治疗偏好。74%患者将治愈列为第一或第二目标(年轻患者86% vs 老年患者52%,p<0.001),72%初诊时偏好积极治疗,85%愿以更多短期风险换取长期更有效治疗;年轻患者更关注第二肿瘤和生育问题,老年患者更关注肺损伤和感染。

要点

  • 74%患者将治愈列为初治第一或第二目标,年轻患者86% vs 老年患者52%(p<0.001)。
  • 72%患者初诊时偏好积极治疗,85%愿接受更多短期风险以换取长期更有效治疗。
  • 年轻患者更担忧第二肿瘤(p<0.001)和生育问题(p=0.007),老年患者更担忧肺损伤(p=0.028)和感染(p<0.001)。

核心结论

  • 调查结果突显了患者治疗偏好,以及治疗目标和长期副作用担忧因患者年龄而异。

研究设计与样本

  • CONNECT患者调查为在线横断面调查,于2020年12月30日至2021年3月1日实施,纳入美国过去10年内确诊的III/IV期经典霍奇金淋巴瘤成人患者182例。

主要发现

  • 确诊时患者中位年龄36岁;66%为年轻患者(16-41岁),34%为老年患者(42-85岁)。
  • 74%患者将治愈列为第一或第二目标,年轻患者86% vs 老年患者52%(p<0.001)。
  • 72%患者初诊时偏好积极治疗,85%愿意接受更多短期风险以换取长期更有效的治疗。
  • 年轻患者较老年患者更担忧第二肿瘤(p<0.001)和生育问题(p=0.007),老年患者更担忧肺损伤(p=0.028)和感染(p<0.001)。
  • 94%患者报告曾有过照护者,其中99%的患者保留了对治疗决策的部分控制权。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We explored patient front-line treatment preferences in newly diagnosed stage III/IV classic Hodgkin lymphoma (cHL). The CONNECT patient survey, administered online from 30 December 2020 to 1 March 2021, examined preferences overall and by age at diagnosis in 182 adult patients diagnosed with stage III/IV cHL within the past 10 years in the United States. At diagnosis, patients' median age was 36 years; 66% of patients were younger (aged 16-41 years) and 34% older (aged 42-85 years). When asked about initial treatment goals, 74% of patients ranked cure as their first or second goal (86% younger vs. 52% older patients; p < 0.001). At diagnosis, 72% of patients preferred aggressive treatment, and 85% were willing to accept more short-term risks in exchange for a better-working therapy long term. For long-term risks, younger versus older patients were significantly more concerned about second cancers (p < 0.001) and fertility issues (p = 0.007), whereas older patients were more concerned about lung damage (p = 0.028) and infections (p < 0.001). Most patients (94%) reported having a caregiver at some point, but 99% of these patients retained some control of treatment decisions. Collectively, these survey results highlight patient treatment preferences and differences in treatment goals and long-term side effect concerns based on patient age.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Flora DR, Parsons SK, Liu N, et al. Patient preferences in the treatment of stage III/IV classic Hodgkin lymphoma: Results from the CONNECT cross-sectional survey. Br J Haematol. 2024. PMID: 38323849. doi:10.1111/bjh.19307

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。